eller"
Novartis Pharma AG, WSJ-027.6.25, CH-4056 Basel, Switzerland
Phone: +41 61 324 4676; Mobile: +41 79 349 7806; phil.l...@novartis.com
"Peter Bonate"
Sent by: owner-nmus...@globomaxnm.com
11/08/2010 17:50
To
"'nmusers@globomaxnm.com'"
cc
Subject
[NMuser
PM
To: 'nmusers@globomaxnm.com'
Subject: [NMusers] Baseline as a covariate
I'd like to get the group's opinion on something. I have a pharmacodynamic
model and the baseline was shown to be a covariate on one of the model
parameters. I was hoping to get general thoughts on the
ilto:owner-nmus...@globomaxnm.com]
On Behalf Of Ken Kowalski
Sent: Wednesday, August 11, 2010 12:12 PM
To: 'Peter Bonate'; nmusers@globomaxnm.com
Subject: RE: [NMusers] Baseline as a covariate
Hi Pete,
In this setting I generally try to first model the baseline response and
perhaps purs
Hi Peter,
I assume from the question that the baseline is the baseline of your
modeled PD measure, not of some other value (like the baseline weight),
and that you model the actual PD measure, not change from the baseline.
Then
- it would be more logical to use the model-predicted baseline;
-
ugust 11, 2010 11:22 AM
To: 'nmusers@globomaxnm.com'
Subject: [NMusers] Baseline as a covariate
I'd like to get the group's opinion on something. I have a pharmacodynamic
model and the baseline was shown to be a covariate on one of the model
parameters. I was hoping to get
I'd like to get the group's opinion on something. I have a pharmacodynamic
model and the baseline was shown to be a covariate on one of the model
parameters. I was hoping to get general thoughts on the use of the baseline as
a covariate. Is there a preference for using the observed baseline v
